ABSTRACT OBJECTIVE: To compare mortality data obtained from randomized controlled trials for the 5 tumor necrosis factor-a (TNF-a) inhibitors used in the treatment of rheumatoid arthritis. METHODS: A systematic review of articles published up to November 2014 was performed using electronic databases. We included randomized, controlled trials, with a follow-up period of at least 24 weeks, comparing TNF-a inhibitors to placebo or disease-modifying antirheumatic drugs. The primary outcome was the occurrence of all-cause mortality. RESULTS: Twenty-three studies were selected. These articles included 6525 patients in the anti-TNF-a group and 3523 in the control group. The duration of patient follow-up ranged from 24 to 104 weeks. The risk of all-cause mortality in patients receiving TNF-a inhibitors was not significantly different from those receiving the comparator (odds ratio 1.32; 95% confidence interval, 0.76-2.29). Subgroup analyses with respect to the molecule used, the dose received, the use of TNF-a inhibitors as monotherapy or combination therapy, or the quality of the trial did not modify the findings. CONCLUSION: This meta-analysis performed on a large number of patients and including the 5 TNF-a inhibitors currently available shows no increased risk of medium-term all-cause mortality in patients with rheumatoid arthritis.
Tumor necrosis factor-a (TNF-a) inhibitors are the most widely used first-line biologic therapy for the treatment of rheumatoid arthritis. Much has been written on the concern that TNF-a inhibitors may increase the risk of malignancy, infections, and other serious adverse events. 1, 2 However, studies of the potential risks of this drug class on the "hard endpoint" mortality are scarce and have provided conflicting results. 3 A previous meta-analysis reported no evidence of increased mortality associated with any TNF-a inhibitor in rheumatoid arthritis. However, the analysis was limited to the 3 TNF-a inhibitors available at this period and mainly included short-term safety data. 4 Thus, our aim was to assess the risk of medium-term all-cause mortality upon the 5 currently available TNF-a inhibitors in rheumatoid arthritis through a meta-analysis of randomized controlled trials.
METHODS

Data Sources and Literature Search
We searched randomized controlled trials using MEDLINE via PubMed, the Cochrane databases, Embase, Google Scholar, and manual searches of reference lists from systematic reviews and original publications. Studies published in English were identified from January 1, 2000 to November 1, 2014. The search terms included TNF alpha inhibitors; adalimumab; etanercept; certolizumab pegol; infliximab; golimumab; rheumatoid arthritis; Randomized controlled trials, mortality; English; All adults. Our research was limited to English language and human clinical trials.
Inclusion Criteria
We defined the target population as adults with rheumatoid arthritis diagnosed according to the 1987 American College of Rheumatology criteria. 5 Interventions included all 5 currently available TNF-a inhibitors. Eligible comparators included placebo and conventional disease-modifying antirheumatic drugs (DMARDs). The primary outcome of this study was the occurrence of all-cause mortality defined on an intentionto-treat basis. To better reflect the drug effect on the potential risk of death, included studies have to report a minimum of 24 weeks of the study duration.
Methodological Quality
The articles that fulfilled the inclusion criteria underwent quality appraisal by using the Jadad scale. 6 
Data Extraction
Two investigators (LP and JA) independently extracted data from articles using a customized form, available from the authors. Disagreements were resolved by consensus.
Statistical Analysis
We used the Mantel-Haenszel method for calculating the weighted summary odds ratio under the fixed-effect model. Next, the heterogeneity was incorporated to calculate summary odds ratios under the random-effects model (DerSimonian and Laird). 7 Statistical heterogeneity was tested by Q-test (c 2 ) and I 2 statistic calculation. 8 All statistical tests and creation of forest plots were conducted with MedCalc software (v11.4.4; Ostend, Belgium). Additional subgroup analyses were planned to check whether they would substantially change the findings.
RESULTS
Included Studies
The results of the article selection process are reported in Figure 1 . Among the 495 studies initially analyzed, 23 studies fulfilled our inclusion criteria ( Table 1) .
9-31 The median study duration was 46 weeks (range: 24 to 104 weeks). This analysis included 10,048 patients: 6525 were treated with TNF-a Figure 1 Flow diagram of articles evaluated for inclusion and exclusion. RA ¼ rheumatoid arthritis.
CLINICAL SIGNIFICANCE
Tumor necrosis factor-a inhibitors show no increased risk of medium-term allcause mortality. The type of molecule and the dose received do not modify this finding. (Figure 2) . The results were consistent across trials (Q ¼ 7.87, P ¼ .99, and I 2 < 25%). Subgroup analysis within the type of comparator did not modify previously observed results. The OR of mortality of patients receiving TNF-a inhibitors used as monotherapy vs placebo was 1.04 (95% CI, 0.20-5.34), and the OR of mortality of patients receiving TNF-a inhibitors used in combination therapy vs conventional DMARDs was 1.36 (95% CI, 0.76-2.43).
Secondary Analyses
Subgroup Analyses with Respect to Each Molecule. Individually, each molecule analyzed separately did not show an increased risk of mortality of any cause ( Table 3) .
Subgroup Analysis with Respect to the Dose of TNF-a Inhibitors. To address the potential dose impact, we compared the mortality event rates according to TNF-a inhibitor dose (high dose, defined by a dose higher than usual TNF-a inhibitor dose as per package insert, vs usual dose). High dose of TNF-a inhibitors was not significantly associated with a significant increase in risk of mortality (OR 0.97; 95% CI, 0.26-3.54 vs 1.43; 95% CI, 0.79-2.59 for the usual dose). Subgroup Analysis with Respect to the Quality of Evidence. Most of our comparison analyses reached a high level of quality of evidence, with a mean Jadad score of 3.87 AE 1.01 (Table 1) . We compared studies with a high quality (Jadad score >3) to those with a lower quality (Jadad score 3). The results did not appear to differ substantially. In high-quality studies, the OR for mortality of any cause was 1.60 (95% CI, 0.78-3.30), and in lower-quality studies, the OR was 0.99 (95% CI, 0.42-2.31).
To help address the potential impact of the calendar time, we also compared mortality according to calendar year of publication (before and after 2006). The summary ORs for mortality were both not significant for these 2 time periods (0.80; 95% CI, 0.37-1.76 before and 2.03; 95% CI, 0.91-4.52 after 2006).
DISCUSSION
A recent meta-analysis has underlined the higher risk of overall serious adverse events in certolizumab pegol-treated patients and the significant increase in the risk of serious infections in patients on adalimumab, certolizumab pegol, and infliximab, which might suggest a potential higher risk of mortality. 1 This hypothesis has not been confirmed in our meta-analysis, which covered the same time period and compared the 5 currently available TNF-a inhibitors for the risk of mortality, an undisputed hard endpoint. Indeed, the use of TNF-a inhibitors is not associated in our study with an increased risk of medium-term mortality.
Several registries have suggested a reduction of the risk of mortality in patients with rheumatoid arthritis treated with TNF-a inhibitors.
32-34 Several factors may explain this discrepancy, especially the inclusion of highly selected patients in randomized controlled trials compared with unselected patients in registries, and the longer time of drug exposure in the latter. This may suggest that registries may be more adequate to address the impact of TNF-a inhibitors on overall mortality. However, our results are consistent with data extracted from the British Society for Rheumatology Biologics Registers and with the meta-analysis of Leombruno.
4,35
Strengths of our meta-analysis are its large sample size, an indirect comparison among the 5 available molecules, the presence of a control group obtained through a process of randomization, the quality of data extracted from a majority of high-quality randomized controlled trials, and the absence of heterogeneity among included trials. Limitations of our metaanalysis included the generalization of our results and the absence of long-term exposition on TNF-a inhibitors. Insufficient data were provided to perform a subgroup analysis according to the duration of use of TNF-a inhibitors. Moreover, effect of TNF-a inhibitors on mortality may occur after discontinuation of these drugs, and this aspect could not be assessed in our meta-analysis.
In conclusion, this meta-analysis shows that treatment with TNF-a inhibitors is not associated with a higher risk of medium-term mortality of any cause in patients with rheumatoid arthritis. These results are reassuring for this duration, given that these therapies are highly effective at controlling symptoms and reducing disability and damage. Further studies are warranted to assess the long-term effect of TNF-a inhibitors on mortality. 16 
